Brainsway ( (BRSYF) ) has released its Q4 earnings. Here is a breakdown of the information Brainsway presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BrainsWay Ltd. is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology. The company operates in the healthcare sector, focusing on improving mental health through innovative treatments.
In its latest earnings report, BrainsWay announced record quarterly sales of $11.4 million for the fourth quarter of 2024, marking a 27% increase compared to the same period in 2023. The company also reported a full-year revenue increase of nearly 30% year-over-year, reaching $41 million, and exceeded its operating income and Adjusted EBITDA margin guidance.
Key financial highlights include a gross margin of 75% for both the fourth quarter and the full year 2024. BrainsWay’s net income for the fourth quarter was $1.5 million, significantly up from $0.1 million in the previous year, while the full-year net income reached $2.9 million, a turnaround from a $4.2 million loss in 2023. The company also completed a $20 million strategic equity financing transaction with Valor Equity Partners and expanded its market presence in Canada and East Asia.
Looking ahead, BrainsWay expects continued strong growth in 2025, with projected revenues between $49 million and $51 million, representing a 20% to 24% increase over 2024. The company anticipates further profitability and positive cash flow, driven by its next-generation Deep TMS 360 system and expanded treatment capabilities.